title: Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, 10903, New Hampshire Avenue, Silver Spring, Maryland, 20993-0002, USA, meiling.chen@fda.hhs.gov.
authors.forename: Mei-Ling
authors.initials: ML
authors.lastname: Chen
authors.forename: Nakissa
authors.initials: N
authors.lastname: Sadrieh
authors.forename: Lawrence
authors.initials: L
authors.lastname: Yu
mesh_terms: D000818:Animals; D001682:Biological Availability; D001702:Biopharmaceutics / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005079:Excipients / Q000737:chemistry / Q000145:classification* / Q000378:metabolism*; D006801:Humans; D009995:Osmosis / Q000187:drug effects / Q000502:physiology; D010539:Permeability / Q000187:drug effects; D012995:Solubility / Q000187:drug effects; D013810:Therapeutic Equivalency
chemical_list: D005079:Excipients